Skyepharma

Skyepharma is a specialist drug delivery company developing oral and inhalation products. With a wide range of patented and proven technologies, Skyepharma helps to make good drugs better. We partner with a wide variety of companies from big Pharma, such as GlaxoSmithKline, Novartis, sanofi-aventis, AstraZeneca and Roche to a range of smaller speciality pharmaceutical companies. Skyepharma’s proprietary drug delivery technologies enable the development of new formulations of existing products as well as new chemical entities to provide a clinical benefit to patients. Skyepharma’s Geomatrix™ and Geoclock™ technologies enable controlled- or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients. The Group’s inhalation technologies include formulation as well as device technologies and encompass metered dose inhalers and dry powder inhalers. With research and development facilities in Switzerland and manufacturing in France, Skyepharma offers a comprehensive range of services from feasibility through to commercial scale manufacture.
Type
Public
HQ
London, GB
Founded
1996
Employees
108 (est)
Skyepharma was founded in 1996 and is headquartered in London, GB

Skyepharma Locations

London, GB
Muttenz, CH

Skyepharma Metrics

Skyepharma Financials

Skyepharma's revenue was £95.9 M in FY, 2015 which is 29.95% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£62.6 M£73.8 M£95.9 M

Revenue growth, %

17.9%29.9%

Cost of sales

£33.2 M£32.9 M£43.1 M

Gross profit

£29.4 M£40.9 M£52.8 M

Gross profit Margin, %

47.0%55.4%55.1%

Operating expense total

£15.8 M£19.3 M£21.3 M

Skyepharma Company Life

You may also be interested in